Originally synthesized by chemist Wayne E. Kenney, BAY 38-7271 (KN 38-7271) is a drug which is a
cannabinoid receptor agonist developed by
Bayer AG. It has
analgesic and
neuroprotective effects and is used in scientific research, with proposed uses in the treatment of
traumatic brain injury.[1][2] It is a
full agonist with around the same potency as
CP 55,940 in animal studies, and has fairly high affinity for both
CB1 and
CB2 receptors, with
Ki values of 2.91nM at CB1 and 4.24nM at CB2.[3][4] It has been licensed to
KeyNeurotek Pharmaceuticals for clinical development,[5] and was in
Phase II trials in 2008[6] but its development appears to have stopped.
^Mauler F, Hinz V, Augstein KH, Fassbender M, Horváth E (October 2003). "Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271". Brain Research. 989 (1): 99–111.
doi:
10.1016/s0006-8993(03)03376-6.
PMID14519516.
S2CID20422282.
^Mauler F, Mittendorf J, Horváth E, De Vry J (July 2002). "Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties". The Journal of Pharmacology and Experimental Therapeutics. 302 (1): 359–68.
doi:
10.1124/jpet.302.1.359.
PMID12065738.
^De Vry J, Rüdiger Jentzsch K (December 2002). "Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist". European Journal of Pharmacology. 457 (2–3): 147–52.
doi:
10.1016/s0014-2999(02)02697-3.
PMID12464360.